Closed Loop Medicine’s Board brings together extensive experience from the life sciences, healthcare, digital health and technology sectors.
Dr Andy Richards CBE has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia and the Babraham Research Campus and is a Director of Ieso Digital Health, CancerResearch Technology (commercial board of CR-UK) and Owlstone Medical. As well as being an advisor to Cambridge Innovation Capital, he also advises the UCL Technology Fund. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a director of The Scale Up Institute.
Dr Richards is a graduate of the University of Cambridge with a PhD in Chemistry.
Chief Executive Officer & Co-Founder
Dr Hakim Yadi CBE is a co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.
As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health – and therefore wealth and well-being -outcomes.
Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.
Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration. Hakim started his career at PA Consulting, where he co-managed the company’s translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).
He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.
Chief Medical and Innovation Officer, Co-Founder & President
Dr Paul Goldsmith was awarded a triple 1st from Cambridge and a clinical scholarship from Oxford. Following general medical training, he sub-specialised in neurology, before completing a PhD in a development biology lab, taking a systems biology approach to understanding human disease. He was the principal founder of DanioLabs Ltd in 2002, which utilised disease modeling for systematic drug repurposing, established discovery programmes in several areas and generated a product pipeline, the most advanced of which now has positive Phase 2 data.
He was then part of the team that reinvigorated Psychology Online Ltd, a digital health company, with a new business plan, management team and financing. He co-founded Rubrum Ltd in 2012 to provide semi-automated healthcare provision in insomnia, pain and COPD to the NHS and other markets through a proprietary online platform and was NED there until 2014. He was also co-founder of Vastrata Ltd, which focused on reprofiling and repurposing, with a virtual business model.
He also has extensive NHS operational and strategic experience, including being NHS England Northern Strategic Clinical Networks (SCN) neuro lead (to May 16), and sitting on a NHS England Urgent and Emergency Care Vanguard and the north Clinical Senate.
Paul is also a Non Executive Director of the UK Medicines & Healthcare products Regulatory Agency (MHRA).
He has in excess of 50 peer reviewed publications and patent applications.
Rebecca began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies, and went on to become Director, Healthcare Ventures at Imperial Innovations (now TouchstoneInnovations).
Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA from Oxford University.
She joined Longwall Ventures after a couple of years sabbatical break spent exploring South America in a VW camper van and focuses predominantly on medical technology opportunities.
Tim joined BGF in January 2018 after actively supporting BGF on a number of projects over the previous 18 months. He is based in London and Cambridge and his main role is to identify and execute investments with a particular focus on tech-oriented propositions.
He also takes a lead role in developing relationships with partners that can help BGF better support key industry sectors. Tim has been active in the venture capital and start-up ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments across a broad range of sectors, stages and geographies. He has recently joined the BGF Investment Committee.
Outside of work Tim spends as much of his time as possible on horseback and, in the interest of combining work with pleasure, keeps a horse specifically for long conference calls. Tim has a science background and began his career in BT’s research labs developing materials for optical switching and amplification. He has an MBA from London Business School.
Clare Terlouw is Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life science sector. She is the head of the investment team and a member of the Early Ventures Investment Committee. Clare oversees the Early Ventures strategy at LifeArc, which is a seed to Series A investment strategy, with the ability to further fund select companies into later rounds of funding. LifeArc’s investment strategy is to seek to generate positive impact on patients and financial returns by investing in early translational sciences and technologies in areas of high unmet patient need.
Clare was previously at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust, where she was Head of Corporate Development. Syncona founds and builds life sciences companies to deliver transformational treatments to patients. She has 15 years of biotech and healthcare financing experience as an investment banker in the City of London, with significant expertise in growth funding for innovative life sciences companies in the private and public markets.
Clare is also a board member of the BioIndustry Association and a non-executive director of Stevenage Bioscience Catalyst.
David Van Sickle
David Van Sickle, PhD, was the co-founder and CEO of Propeller Health, a respiratory digital health and therapeutics company, which pioneered the application of digital technology to chronic disease management and pharmaceutical therapy.
In 2019, the company was acquired by ResMed (NYSE: RMD). David continued to lead the business until 2021 when he transitioned to a role as an Entrepreneur-in-Residence.
From 2017-2020, he served as a founding board member of the Digital Therapeutics Alliance, a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
David received a PhD in medical anthropology from the University of Arizona in 2004. Between 2004-6, he was an Epidemic Intelligence Service officer at the US Centers for Disease Control and Prevention. From 2006 to 2009, David was a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. In 2010, he was named a Champion of Change by the Obama administration for work on technology and innovation.
Find out more
Get in touch if you would like to speak with one of our team.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.